# ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer

> **NCT03950570** · PHASE1,PHASE2 · COMPLETED · sponsor: **Orinove, Inc.** · enrollment: 58 (actual)

## Conditions studied

- Advanced Solid Tumor
- Metastatic Breast Cancer

## Interventions

- **DRUG:** Abraxane
- **DRUG:** ORIN1001

## Key facts

- **NCT ID:** NCT03950570
- **Lead sponsor:** Orinove, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-25
- **Primary completion:** 2023-01-30
- **Final completion:** 2023-01-30
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2024-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03950570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03950570, "ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT03950570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*